Skip to main content

Table 2 Clinicopathologic characteristics according to breast cancer phenotype

From: Succinate dehydrogenase expression in breast cancer

Parameters Total n = 721 (%) Luminal A n = 302 (%) Luminal B n = 168 (%) HER-2 n = 69 (%) TNBC n = 182 (%) P-value
n = 302 (%) n = 168 (%) n = 69 (%) n = 182 (%)
Age (years, mean ± SD) 49.6 ± 10.9 50.6 ± 10.4 48.4 ± 10.0 52.4 ± 10.0 48.0 ± 12.4 0.005
Histologic grade       <0.001
 I 120 (16.6) 92 (30.5) 20 (11.9) 1 (1.4) 7 (3.8)  
 II 364 (50.5) 182 (60.3) 91 (54.2) 36 (52.2) 55 (30.2)  
 III 237 (32.9) 28 (9.3) 57 (33.9) 32 (46.4) 120 (65.9)  
Tumor stage       0.007
 T1 350 (48.5) 167 (55.3) 85 (50.6) 30 (43.5) 68 (37.4)  
 T2 356 (49.4) 127 (42.1) 81 (48.2) 38 (55.1) 110 (60.4)  
 T3 15 (2.1) 8 (2.6) 2 (1.2) 1 (1.4) 4 (2.2)  
Nodal stage       0.060
 N0 425 (58.9) 171 (56.6) 92 (54.8) 42 (60.9) 120 (65.9)  
 N1 192 (26.6) 89 (29.5) 43 (25.6) 13 (18.8) 47 (25.8)  
 N2 65 (9.0) 27 (8.9) 18 (10.7) 9 (13.0) 11 (6.0)  
 N3 39 (5.4) 15 (5.0) 15 (8.9) 5 (7.2) 4 (2.2)  
Estrogen receptor status       <0.001
 Negative 261 (36.2) 5 (1.7) 5 (3.0) 69 (100.0) 182 (0.0)  
 Positive 460 (63.8) 297 (98.3) 163 (97.0) 0 (0.0) 0 (0.0)  
Progesterone receptor status       <0.001
 Negative 346 (48.0) 49 (16.2) 46 (27.4) 69 (100.0) 182 (100.0)  
 Positive 375 (52.0) 253 (83.8) 122 (72.6) 0 (0.0) 0 (0.0)  
HER-2 status       <0.001
 Negative 573 (79.5) 302 (100.0) 89 (53.0) 0 (0.0) 182 (100.0)  
 Positive 148 (20.5) 0 (0.0) 79 (47.0) 69 (100.0) 0 (0.0)  
 Ki-67 LI (%, mean ± SD) 17.3 ± 18.4 4.7 ± 3.7 19.6 ± 12.6 19.3 ± 12.8 35.1 ± 23.0 <0.001
Tumor recurrence 63 (8.7) 14 (4.6) 13 (7.7) 11 (15.9) 25 (13.7) 0.001
Patient death 60 (8.3) 12 (4.0) 13 (7.7) 11 (15.9) 24 (13.2) <0.001
Duration of clinical follow-up (months, mean ± SD) 70.0 ± 31.2 72.4 ± 29.3 70.2 ± 30.0 65.2 ± 34.3 67.8 ± 34.2 0.234
  1. TNBC triple negative breast cancer.